JPET

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jackson, E. K.
Right arrow Articles by Tofovic, S. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jackson, E. K.
Right arrow Articles by Tofovic, S. P.

Vol. 299, Issue 3, 978-987, December 2001

A1 Receptor Blockade Induces Natriuresis with a Favorable Renal Hemodynamic Profile in SHHF/Mcc-facp Rats Chronically Treated with Salt and Furosemide

Edwin K. Jackson , Curtis K. Kost, Jr. , William A. Herzer, Glenn J. Smits and Stevan P. Tofovic

Center for Clinical Pharmacology (E.K.J., C.K.K., W.A.H., S.P.T.), Departments of Pharmacology (E.K.J.) and Medicine (E.K.J., C.K.K., S.P.T.), University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania; and Biogen, Inc., Cambridge, Massachusetts (G.J.S.)

Our goal was to test the hypothesis that A1 receptor blockade induces diuresis/natriuresis with a favorable renal hemodynamic/cardiac profile in aged, lean SHHF/Mcc-facp rats, a rodent model of hypertensive dilated cardiomyopathy. Thirteen-month-old SHHF/Mcc-facp rats were pretreated for 72 h before experiments with furosemide (100 mg/kg by gavage 72, 48, and 24 h before experiments) to mimic the clinical setting of chronic diuretic therapy and were given 1% NaCl as drinking water to reduce dehydration/sodium depletion. Animals were instrumented for measurement of systemic and renal hemodynamics, renal excretory function, and cardiac performance, and baseline values were obtained during a 30-min clearance period. Animals then received either vehicle (n = 9), BG9719 [the S-enantiomer of 1,3-dipropyl-8-[2-(5,6-epoxynorbornyl)] xanthine (also called CVT-124)] (highly selective A1 receptor antagonist; 0.1 mg/kg bolus + 10 µg/kg/min; n = 9) or furosemide (loop diuretic; 30 mg/kg; n = 8) and measurements were repeated during four subsequent clearance periods. Both BG9719 and furosemide increased urine volume and absolute and fractional sodium excretion. BG9719 increased renal blood flow and glomerular filtration rate, but did not affect fractional potassium excretion. Furosemide decreased renal blood flow and glomerular filtration rate and increased fractional potassium excretion. Neither drug altered afterload; however, furosemide, but not BG9719, decreased preload (central venous pressure and ventricular end diastolic pressure). Neither drug altered systolic function (+dP/dtmax); however, furosemide, but not BG9719, attenuated diastolic function (decreased -dP/dtmax, increased tau). In the setting of left ventricular dysfunction, chronic salt loading and prior loop diuretic treatment, selective A1 receptor antagonists are effective diuretic/natriuretic agents with a favorable renal hemodynamic/cardiac performance profile.


0022-3565/01/2993-0978$03.00/0
THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Copyright © 2001 by The American Society for Pharmacology and Experimental Therapeutics



This article has been cited by other articles:


Home page
Eur J Heart FailHome page
V. Vallon, C. Miracle, and S. Thomson
Adenosine and kidney function: Potential implications in patients with heart failure
Eur J Heart Fail, February 1, 2008; 10(2): 176 - 187.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
E. M. deGoma, R. H. Vagelos, M. B. Fowler, and E. A. Ashley
Emerging Therapies for the Management of Decompensated Heart Failure: From Bench to Bedside
J. Am. Coll. Cardiol., December 19, 2006; 48(12): 2397 - 2409.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
X. Zhou and C. K. Kost Jr.
Adenosine A1 Receptor Antagonist Blunts Urinary Potassium Excretion, but Not Renal Hemodynamic Effects, Induced by Carbonic Anhydrase Inhibitor in Rats
J. Pharmacol. Exp. Ther., February 1, 2006; 316(2): 530 - 538.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2001 by the American Society for Pharmacology and Experimental Therapeutics.